Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC (Evolution)
Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study
Sponsor: Kobe Minimally Invasive Cancer Center
This PHASE2 trial investigates Locally Advanced Non-small Cell Lung Cancer and is currently actively recruiting participants. Kobe Minimally Invasive Cancer Center leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Oct 2025 — Present [monthly]
Not Yet Recruiting PHASE2
Status: Unknown → Not Yet Recruiting
-
Sep 2024 — Oct 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2022 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kobe Minimally Invasive Cancer Center
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.